65,437 trials
Healthy
Primary: Area Under the Concentration-time Curve of Pramipexole in Plasma at Steady State Over 24 Hours (AUC0-24,ss); in Case of ER up to the Time Point of Next Dosing…
Multiple Sclerosis
Primary: Summary of Treatment Emergent Adverse Events (TEAE). — 205; 39; 46; 7 participants
Cancer
Primary: Maximum Tolerated Dose (MTD) — NA; NA; 590; 590 mg
Irritable Bowel Syndrome
Primary: IBS (Irritable Bowel Syndrome) Symptom Severity Score (Total Score) — 256.9; 84.4 units on a scale
Osteoarthritis
Primary: Change in Western Ontario and McMaster Universities (WOMAC) Pain Questionnaire Subscore From Baseline — -43.4; -41.1; -34.0 mm
Arthritis · Osteoarthritis, Knee · Osteoarthritis, Hip
Primary: Summary of Change From Day 3 to Day 1 in Maximum Anti-Factor Xa (aFXa) — 1.66; 1.83 IU/ml — p=.008
Methamphetamine Dependence
Primary: Side Effects Checklist — 9.6515 units on a scale — p=0.05
Cataract · Aphakia
Primary: Refractive Stability — 17; 23; 25; 25 Eyes
Asthma
Primary: Urinary Free Cortisol (UFC) — 0.86; 1.03 Ratio
Kidney Failure, Acute
Primary: Adverse Drug Events or Potential Adverse Drug Events — 99; 104 Patient-Medication Pairs
Multiple Sclerosis
Primary: Summary of Treatment Emergent Adverse Events (TEAE). — 264; 94; 77; 37 Participants
Pain, Postoperative
Primary: Percent of Patients Without Device Failure — 100 percent
Attention Deficit Hyperactivity Disorder
Primary: Safety Assessment in Terms of Adverse Events (Treatment-emergent [TEAEs] and Serious [SAEs]) — 301; 246; 178; 2 Participants
Cancer
Primary: Maximum Tolerated Dose (MTD) — 610 mg
Cerebral Infarction · Brain Ischemia
Primary: Number of Patients With a Modified Rankin Scale (mRS) Score of 0-1 at 3 Months — 38 participants